Exelixis (EXEL)
(Delayed Data from NSDQ)
$20.34 USD
-0.23 (-1.12%)
Updated May 28, 2024 04:00 PM ET
After-Market: $20.32 -0.02 (-0.10%) 5:00 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Brokerage Reports
Exelixis, Inc. [EXEL]
Reports for Purchase
Showing records 21 - 40 ( 178 total )
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
An Oncology-Focused Targeted Therapy Powerhouse; Initiate at Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended July 21.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department